Novartis’ Farydak Gains FDA Approval On Strength Of Subgroup Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency grants accelerated approval of the HDAC inhibitor for third-line multiple myeloma after an advisory committee recommended against use in the broader relapsed setting due to the drug’s toxicities.